Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Pediatric Brain Tumors Market Growth in 2025?
In recent times, the market size of pediatric brain tumors has seen substantial growth. It is projected to advance from a value of $1.4 billion in 2024 to a value of $1.5 billion in 2025, signalling a compound annual growth rate (CAGR) of 7.1%. Factors contributing to this acceleration in the historical period include a spike in cases of pediatric brain tumors, evolving economies, increased focus on research and development, and a heightened need for diagnostic technology. Moreover, global cases of pediatric tumors are on the rise.
What Is the Forecast for the Pediatric Brain Tumors Market Size Through 2029?
Expectations for the pediatric brain tumor market show a robust increase in the coming years, with projections for a rise to $1.83 billion in 2029 and a CAGR of 5.1%. Factors responsible for this prospective growth include precision medicinal practices, molecular profiling, specifically targeted therapies, improved healthcare systems, and a wider insurance coverage. Foreseen trends of this period are enhancements in methodologies such as magnetic resonance imaging (MRI), positron emission tomography (PET), and computed tomography (CT) scanning. Additionally, the utilization of genetic and molecular profiling, the creation of targeted treatments, the implementation of immunotherapies, and the emergence of minimally invasive surgical approaches all play a vital role.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21248&type=smp
What are the Key Market Players in Pediatric Brain Tumors Market and How They’re Evolving?
Major companies operating in the pediatric brain tumors market are AbbVie Inc., Bayer AG, Novartis AG, Roche Holding AG, Takeda Pharmaceutical Company, UCLA Health, Ipsen Pharma, Novocure, Blueprint Medicines, Karyopharm Therapeutics Inc., Renaissance Pharma, Servier Laboratories, Matica Biotechnology, Curis Inc., Oncoheroes Biosciences, Treovir Inc., Plus Therapeutics Inc., Stemline Therapeutics Inc., BrainChild Bio Inc., Seattle Children’s Therapeutics
What Are the Primary Growth Drivers in the Pediatric Brain Tumors Market?
The pediatric brain tumors market is expected to experience significant growth due to an increasing demand for personalized medicine. This strategic approach to healthcare tailors treatments and medical decisions to an individual’s genetic makeup, lifestyle and unique health needs. Developments in genetic research, improvements in diagnostic tools, and the capacity for targeted treatments stimulate the demand for personalized medicine. As a result of treating the specific type of tumor, mutation and response of the child, personalized medicine offers targeted therapies that are more potent and inflict less damage to healthy tissues, thus increasing outcomes and minimising side effects. For example, the Personalized Medicine Coalition, a US-based healthcare and hospital organization reported that in February 2024, 16 new personalized therapies for rare diseases patients were granted FDA approval, a notable increase from six in 2022. Hence, the rise in demand for personalized medicine is fueling the expansion of the pediatric brain tumor market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21248&type=smp
What Are the Leading Segments in the Global Pediatric Brain Tumors Industry?
The pediatric brain tumors market covered in this report is segmented –
1) By Type: Gliomas, Mixed Neuronal-Glial Tumors, Embryonal Tumors, Choroid Plexus Papilloma Or Carcinoma, Tumors Arising From Non-Neuroepithelial Tissue, Meningeal Tumors
2) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Immunotherapy
3) By Diagnosis Method: Imaging Techniques, Biopsy, Neurological Exam, Lumbar Puncture
4) By Age Group: Infants, Toddlers, Children, Adolescents
5) By Application: Hospitals And Clinics, Medical Research Centers, Academic Institutes, Other Applications
Subsegments:
1) By Gliomas: Low-Grade Gliomas, High-Grade Gliomas
2) By Mixed Neuronal-Glial Tumors: Gangliogliomas, Dysembryoplastic Neuroepithelial Tumors (DNET)
3) By Embryonal Tumors: Medulloblastoma, Atypical Teratoid Rhabdoid Tumor (ATRT), Primitive Neuroectodermal Tumors (PNET)
4) By Choroid Plexus Papilloma or Carcinoma: Choroid Plexus Papilloma, Choroid Plexus Carcinoma
5) By Tumors Arising from Non-Neuroepithelial Tissue: Rhabdomyosarcoma, Ewing’s Sarcoma
6) By Meningeal Tumors: Meningiomas, Hemangiopericytomas
What Are the Key Market Trends in the Pediatric Brain Tumors Industry?
Prominent organizations in the pediatric brain tumors market are concentrating on creating advanced treatments like Type II RAF inhibitors to augment targeted therapies and promote improved results for patients. Type II RAF inhibitors are specialized therapies that inhibit RAF kinases, particularly those related to mutations which facilitate tumor growth. Crafted to target irregular RAF protein formations discovered in distinct pediatric low-grade glioma (pLGG) subcategories, these inhibitors successfully block the erroneous signaling pathways causing tumor cell multiplication and existence. For example, in April 2024, the U.S. FDA granted Day One Biopharmaceuticals, a US biotech firm, expedited approval for OJEMDA (tovorafenib), meant for treating relapsed or unresponsive pediatric low-grade glioma (pLGG) in patients of 6 months and above bearing specific BRAF alterations. Such approval turns OJEMDA into the first FDA-sanctioned therapy aimed at BRAF fusions or mutations within this demographic. The sanction hinges on the documented overall response rate of 51% from FIREFLY-1 clinical trial checking the drug’s effectiveness in this symptom. This therapy is particularly geared towards minors with brain tumor unresponsive to earlier treatments.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/pediatric-brain-tumors-global-market-report
What Is the Regional Outlook for the Pediatric Brain Tumors Market?
North America was the largest region in the pediatric brain tumors market in 2024. The regions covered in the pediatric brain tumors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21248
This Report Delivers Insight On:
1. How big is the pediatric brain tumors market, and how is it changing globally?
2. Who are the major companies in the pediatric brain tumors market, and how are they performing?
3. What are the key opportunities and risks in the pediatric brain tumors market right now?
4. Which products or customer segments are growing the most in the pediatric brain tumors market?
5. What factors are helping or slowing down the growth of the pediatric brain tumors market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
